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Abstract: RPGR exon ORF15 variants are one of the most frequent causes for inherited retinal
disorders (IRDs), in particular retinitis pigmentosa. The low sequence complexity of this mutation
hotspot makes it prone to indels and challenging for sequence data analysis. Whole-exome sequencing
generally fails to provide adequate coverage in this region. Therefore, complementary methods are
needed to avoid false positives as well as negative results. In this study, next-generation sequencing
(NGS) was used to sequence long-range PCR amplicons for an IRD cohort of African ancestry.
By developing a novel secondary analysis pipeline based on de novo assembly, we were able to avoid
the miscalling of variants generated by standard NGS analysis tools. We identified pathogenic variants
in 11 patients (13% of the cohort), two of which have not been reported previously. We provide a
novel and alternative end-to-end secondary analysis pipeline for targeted NGS of ORF15 that is less
prone to false positive and negative variant calls.
Keywords: RPGR; ORF15; RP; de novo assembly; diagnostics; genetic testing; secondary analysis
1. Introduction
Retinitis pigmentosa (RP) is an inherited retinal disorder (IRD) that is characterised by the loss
of retinal rod photoreceptor cells [1]. The initial symptom is usually nightblindness, followed by
progressive constriction of the peripheral visual fields, leading to tunnel vision [2]. As the disease
progresses, cone photoreceptor cells are inevitably affected, which can result in total blindness. RP is
the most common IRD, with an estimated prevalence of about 1 in 3500–4000 individuals [1,3], and it
can be inherited as an autosomal dominant (ad, 15–25%), autosomal recessive (ar, 35–50%) or an
X-linked (xl, 7–15%) trait [3]. Simplex or isolated cases are also common [3,4].
A genetic diagnosis for IRD patients can confirm a clinical diagnosis, provide a clearer prognosis,
form the basis of genetic counselling for families, and allow participation in gene-based therapy
trials [5]. However, it is impossible to predict the causative RP gene based solely on phenotype and
Genes 2020, 11, 800; doi:10.3390/genes11070800 www.mdpi.com/journal/genes
Genes 2020, 11, 800 2 of 17
inheritance pattern. RP is usually monogenic, yet an expansive list of genes has been associated with
the disease (RetNetTM, https://sph.uth.edu/retnet/). In addition to the exceptional genetic heterogeneity,
phenotypic variability also occurs, complicating molecular analysis even further. However, it can be
generalised that xlRP cases display some of the most severe RP phenotypes in males, with early age of
onset (childhood to late teen years) and rapid disease progression [4,6]. To date, two major causative
xlRP genes have been identified, RP2 and RPGR, and they account for 10–20% and 50–90% of cases,
respectively [4,6–9]. In addition, a deep intronic mutation in the syndromic ciliopathy gene, OFD1,
has been identified in one family with severe non-syndromic xlRP [10].
The systematic screening of all RP genes in a cohort of patients using a candidate approach is
challenging and costly due to the marked phenotypic and genetic heterogeneity described. Thus,
next-generation sequencing (NGS) approaches such as whole exome sequencing (WES) or targeted
resequencing are revolutionising molecular diagnostics in heterogeneous Mendelian diseases such as
IRD, and specifically RP [11,12]. Still, accurate clinical information such as individual disease status,
phenotypes, and mode of inheritance within a family are crucial. With ambiguities in these data,
downstream analysis and variant prioritisation for mutation identification is impeded. For example,
whilst males are exclusively affected in most X-linked recessive Mendelian disorders, female carriers
of xlRP gene mutations may manifest with a spectrum of disease [3,6,13–21], which can result in a
pedigree displaying an apparent ad trait. The incorrect assumption of disease inheritance (thereby,
interrogating autosomal rather than xl variants) may cause false negative results.
One limitation of capture-based NGS is that a critical xlRP mutational hotspot is inadequately
captured. The RPGR gene was identified as causing xlRP in 1996. Four years later, an RPGR transcript
with a novel 3′ terminal exon, known as exon open reading frame 15 (ORF15), was identified [22].
ORF15 was reported as a mutational hotspot, accounting for the majority of xlRP cases studied.
Multiple isoforms of RPGR exist, and the isoform containing ORF15 is the predominant transcript
expressed in the retina [22,23]. ORF15 includes exon 15 and a portion of intron 15, and it is comprised
of a highly repetitive, low-complexity, purine-rich sequence. The nature of this sequence has been
postulated to be responsible for the region’s high mutability, possibly by adopting unusual structural
conformations, thereby reducing the replication fidelity [22]. Additionally, this genomic sequence
generates technical challenges in molecular investigations. It has been shown that the RPGR exon
ORF15 is difficult to sequence, using conventional Sanger sequencing as well as NGS approaches, due
to the highly repetitive sequence exceeding 1 Kb in length [24]. Huang et al. showed that ORF15 was
insufficiently captured during NGS, causing false negative results. Therefore, they proposed that a
complementary approach be taken in the molecular diagnosis of IRDs, with additional sequencing of
targets such as RPGR ORF15, which evade capture-based technologies [24].
In an effort to elucidate the genetic landscape of IRD among the indigenous African populations
of South Africa (SA), WES was previously performed in a cohort of 16 families, and a molecular
diagnosis obtained for approximately 40% through an analysis of all reported IRD genes at that time
(n = 285) [25]. Leveraging the vast genomic diversity of indigenous Africans in SA [26–31] yielded
several novel mutations [25] and assisted the identification of a novel IRD gene [32]. Subsequently,
the WES data from five unresolved families with an absence of male-to-male disease transmission were
re-interrogated, confirming that ORF15 had been insufficiently captured. For 4/5 families, affected
males within a family shared a haplotype spanning the region of interest. The genetic testing of RPGR
exon ORF15 in those four probands identified two mutations in three families: c.2790_2791delGG;
p.Glu931GlyfsTer147 and c.2964_2965delGG; and p.Glu989GlyfsTer89 (Figure S1). Both mutations
had been previously associated with xlRP [33,34]. Therefore, supplementary analysis of ORF15 had
resulted in identification of the probable causal mutation in 3/16 families (19%). The high detection
rate premised our current study of the mutation hotspot in a larger cohort of indigenous African IRD
patients as a pre-screen, prior to embarking on further WES.
NGS data analysis workflow can be divided into three stages of analysis: primary, secondary,
and tertiary [35]. Briefly, primary analysis converts raw signals (i.e., images) into nucleotides sequences
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(FASTQ file generation). Secondary analysis aligns the sequences to a reference build (BAM file
generation) or assembles a sequence de novo (contig file generation) and performs variant detection
(VCF file generation). Finally, tertiary analysis involves the annotation of the resulting data and
their interpretation. We report here a novel secondary analysis pipeline based on de novo assembly,
which identified pathogenic variants in 11 patients (13% of the African cohort).
2. Materials and Methods
2.1. Patient Cohort
The University of Cape Town (UCT) IRD registry currently contains biological material, clinical
information, and demographic data of 3506 individuals from 1617 SA Families with IRD. Informed
consent was obtained according to the 2013 Declaration of Helsinki for all participants from whom
samples have been archived. Ethics approval was granted by the Human Research Ethics Committee
of the UCT Faculty of Health Sciences (REC REF: 226/2010 and 768/2013). Samples from the registry
have been investigated over the years in various research projects, and only genetically unresolved
indigenous African IRD cases were included in the present study. All individuals with pedigrees
displaying male-to-male transmission of disease were excluded. The cohort comprised isolated males
with RP (n = 65), probands with a family history suggestive of adRP, arRP, or xlRP (n = 17) and
probands with recessive or sporadic macular degeneration (n = 15).
2.2. DNA Extraction
The UCT IRD registry and biobank has archived biological material from patients for three
decades; therefore, various DNA extraction methods have been used over the years. Blood samples
were collected in EDTA tubes and processed immediately, mainly using a salting out method [36],
although different commercial DNA extraction kits have been trialled for short periods at various times.
Alternatively, the buffy coat was removed from the blood sample and frozen, and it was later processed
using the salting out method. Since 2013, saliva samples have been collected using Oragene® collection
kits (DNA Genotek Inc, Ottawa, Canada) and processed according to the manufacturers’ instructions.
DNA samples were quantified using the Nanodrop ND-1000 Spectrophotometer (Thermo Fisher
Scientific, Waltham, MA, USA) and subsequently diluted to a final concentration of 20 ng/µL in
Sabax water (Adcock Ingram, Johannesburg, SA). After dilution, the DNA integrity was confirmed
using 1–2% weight/volume (w/v) agarose gels containing 0.5–1 g agarose (Lonza SeaKem® LE, Basel,
Switzerland), 50 mL of 1X Tris Borate EDTA (TBE) buffer and 5 µL SYBR® Safe DNA Gel Stain (Thermo
Fisher Scientific).
2.3. ORF15 NGS Amplification and Sequencing
The RPGR ORF15 was amplified and sequenced as previously described [37]. Briefly, primers
were used to amplify a 2.1 kb region covering the entire exon ORF15 (hg19 chrX:38144633-38146732).
Then, the amplicons were sheared in a microTUBE-50 AFA with a Covaris M220 instrument (Covaris,
USA) to a mean size of 273 bp with the following settings: 75 W peak incident power, 10% duty factor,
200 cycles per burst, 170 s treatment time. Indexed DNA libraries were constructed with a TruSeq DNA
Nano kit according to the manufacturer’s protocol (Illumina, San Diego, CA, USA). After end repair,
size selection, A-tailing, indexed adapter ligation, and a last amplification step, the libraries were
validated on a Bioanalyzer 2100 (Agilent, Santa Clara, CA, USA) and quantified with the Qubit dsDNA
High sensitivity kit (Thermo Fisher Scientific). Final libraries were diluted to 4 nM for denaturation
and prepared to a 12 pM solution for paired-end sequencing (2 × 151 cycles) on a MiSeq instrument
with a MiSeq Reagent V2 (300-cycles) cartridge (Illumina).
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2.4. NGS Data Analysis
Demultiplexed data were aligned to the Human reference genome hg19 by BWA-MEM
(Burrows-Wheeler aligner), and variant calling was performed by GATK (Genome Analysis ToolKit).
Additionally to this standard secondary analysis pipeline, FASTQ files also underwent de novo
assembly with SPAdes (St. Petersburg genome assembler) [38]. The resulting contigs were filtered
based on G-content and then scored based on size and coverage. If no appropriate contig was found
(G-content <15%, size >2000 and <2300 bp, and coverage >30), the highest scoring contigs, together
with the RPGR reference sequence, were given as trusted contig inputs in a second SPAdes assembly
run with different kMER settings. The resulting contigs were scored again and selected. If still no
appropriate contig was found, a third and final SPAdes assembly run was performed to resolve the last
samples with kMERs 77, 99, and 127, the highest scoring contigs generated in the previous assembly
steps as untrusted contigs, and the RPGR reference sequence as trusted contig inputs.
Then, the final contigs were aligned to the reference RPGR ORF15 sequence with MAFFT v7
(Multiple Alignment using Fast Fourier Transform) and screened for variants using SNP-sites for
single-nucleotide variants (SNVs) and an in-house Python 3 (https://www.python.org) script for
indels [39,40]. Finally, detected variants were annotated for frequency (gnomAD) [41]. The entire
de novo assembly-based pipeline from FASTQ to gnomAD-annotated VCF is included in the
Supplementary Materials, Zipped Folder S2, as a JupyterLab notebook (https://jupyterlab.readthedocs.
io/en/stable/). Patient NGS data are not available, due to privacy or ethical restrictions. The vast
majority of reported pathogenic mutations in ORF15 (i.e., 257/259 variants in the Human Gene Mutation
Database, HGMD®, and all variants in a gene-specific variant database) are frameshift or nonsense
variants [42–44]. While it is possible that silent or missense variants may be pathogenic, these require
extensive segregation analyses and functional studies to prove causality. Therefore, in this study, we
prioritised only nonsense and frameshift variants.
2.5. Confirmation by Sanger Sequencing
Likely pathogenic variants were confirmed by Sanger sequencing and cosegregation analysis was
performed in available familial samples. Moreover, assumed false positives and negatives generated
by the standard pipeline were verified by Sanger sequencing when possible. A 1953 bp fragment
spanning the coding region of ORF15 was amplified from 200 ng genomic DNA, using previously
published primers ORF15-F3 and ORF15-R6 [45]. PCR was performed with the HotStarTaq® kit
(QIAGEN, Hilden, Germany), using the following cycling conditions: 95 ◦C—15 min, 45 cycles of
{94 ◦C—45 s, 60 ◦C—1 min, 72 ◦C—3.5 min}, 72 ◦C—10 min, 10 ◦C hold.
Following purification with FastAP™ Thermosensitive Alkaline Phosphatase (Thermo Fisher
Scientific) and Exonuclease I (Thermo Fisher Scientific), sequencing was performed with published
primers ORF15-R7b, -R8b, -R8c, or -R9 [45] (depending on the location of the putative mutation), using
BigDye® Terminator v3.1 Ready Reaction Mix (Applied Biosystems by Thermo Fisher Scientific) and
Q-Solution (QIAGEN).
Cycle sequencing products were purified by ethanol precipitation, and 5 µL purified sequencing
reaction was added to 8 µL Hi-Di™ Formamide (Applied Biosystems by Thermo Fisher Scientific).
Capillary electrophoresis was performed on an ABI Prism 3130xl Genetic Analyser (Applied Biosystems
by Thermo Fisher Scientific). Output.ab1 files were aligned to the reference ORF15 sequence
(NM_001034853.2) using Bioedit [46] and manually inspected for the specific variants identified
by NGS, utilising Mutalyzer [47] to confirm the flanking sequences.
3. Results
3.1. NGS PCR and Sequencing Efficiency
Amplification of the ORF15 region of RPGR was possible for 82 of the 97 samples included in this
study (85%). It was not possible to associate sample characteristics (such as extraction method, sample
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type, or sample age) to unsuccessful amplification. It is possible that variants in the primer-binding
regions prevented amplification, at least in a subset of these samples.
The average DNA concentration after PCR for the successful samples was 35.1 ng/µL (range
5.4–132.0 ng/µL). The average maximum read depth in the ORF15 region after BWA-MEM alignment
equalled 5346 reads.
3.2. De Novo Assembly Improves Diagnostic Sensitivity
RPGR’s ORF15 repeatedly proved itself not only challenging in terms of sequencing data generation,
but also during subsequent data analysis. The standard NGS pipeline, consisting of reads alignment to
the reference genome with BWA-MEM followed by variant calling with GATK, is not sufficient for
this low-complexity region. Specifically, it often resulted in erroneous “heterozygous” calls in males,
and it was particularly poor at detecting larger indels (≥20 bp). In fact, there were 606 total and 43
unique variants called across all sequenced samples that passed all quality filters; of the 606 variants,
546 were called as heterozygous, and of these, 432 (79%) were found in male samples. Furthermore,
the standard analysis pipeline produced both false positives and false negative results.
To overcome this obstacle, we created an alternative Python-based pipeline (available in the
Supplementary Materials, Zipped Folder S2 and HTML S3) integrating the de novo assembly software
SPAdes, the multi-fasta aligner MAFFT v7, and the SNVs’ identified SNP sites [38–40]. To our
knowledge, this is the first report of a de novo assembler being used for molecular diagnostic
applications for inherited diseases. Briefly, SPAdes’ output is a FASTA file containing several
(sometimes many) contigs. These contigs were scored based on size (<2300 and >400) and coverage
as (>30) a pre-selection step. The reference sequence (plus strand) of the amplicon has less than 7%
G-content. This characteristic was used to filter out unrelated contigs. In addition, MAFFT does not
reverse complement; therefore, it is necessary that the selected contigs are from the same strand as
the input reference sequence. For this reason, if the contig does not fulfill the G-content threshold,
its reverse complement is checked for the same criterion. A satisfactory contig (size <2300 and >2040)
was assembled and selected for 46/82 samples (56%). The other FASTQ files underwent a second
round of assembly with SPAdes using the pre-selected top-scoring contigs (maximum 5 contigs) and
the RPGR reference sequence as trusted contigs and different kMER settings. The second assembly
step resulted in a final contig for 35 of the 36 remaining samples (97%). A third and final SPAdes
assembly step was performed to resolve the last sample. When sequencing PCR amplicons with NGS,
the primer-binding regions are generally over-represented compared to the rest of the amplicon; that
causes some of the contigs to be larger than expected (up to 2258 bp in this cohort).
Then, the final contigs were aligned back to the reference RPGR sequence of the 2.1 kb amplicon
using MAFFT v7 [39]. SNVs were called by SNP sites and indels were called by an in-house Python
script [40]. Finally, all variants were annotated for their gnomAD frequency [41].
The Python pipeline allowed for the identification of indels in the low-complexity region that
were otherwise missed by the standard NGS pipeline. Table 1 summarises the alternative pipeline
findings for our cohort and shows whether the variant had been identified by the standard pipeline
and whether it was confirmed by Sanger sequencing. The analysis revealed pathogenic variants in
11 patients (13.4%), including three recurrent mutations and two previously unreported frameshift
mutations [7,22,33,34,48].
The identified indels could be confirmed in at least a subset of carriers. The novel pipeline called
the c.2660_2661insGGAAGAGGAGGAAGGAGAAGGGGAGGGAGAAGAGGAAGGAGAAGGGGA
GGG, c.2639A>G and c.2633_2634delinsAA variants in sample Afr-61; however, Sanger sequencing
revealed that sample Afr-61 actually carries the c.2606_2632dup and an additional variant close-by:
c.2670_2693dup (gnomAD (%) = 0.0016). The underlying sequence for either variant combination is
the same; these are merely two different ways to call the variants compared to the reference sequence.
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Table 1. Spectrum of variants identified in the cohort by the novel pipeline. Variant nomenclature based on hg19 with the corresponding gnomAD overall frequency
(when available) and the number of samples in the cohort carrying each variant. Column “Std pipeline” displays whether the variant was identified by the standard
pipeline or not. The “Sanger” column shows whether the variant was identified in the available sequences. Variants highlighted in grey and in italics are confirmed
false positives. Bold orange variants were considered pathogenic. * denotes variants that have been flagged as low quality on gnomAD. † denotes variants for which
only a subset of samples was verified by Sanger.
cNomen (NM_001034853.2) pNomen # of Samples gnomAD (%) rsID Pathogenicity Std Pipeline Sanger First Report
c.*125delA 52 31.2591 rs35637775 Benign No
c.3407G>A p.Gly1136Asp 2 0.2171 rs150960964 Benign Yes
c.3396C>T p.= 4 16.1297 rs12687163 Benign Yes
c.3264G>A p.= 14 7.7524 rs78736275 Benign Yes
c.3219C>T p.= 14 7.7934 rs111787313 Benign Yes Yes †
c.3178_3179del p.Glu1060ArgfsTer18 1 0.0011 rs771214648 Pathogenic Yes Yes 1
c.3108_3122del p.Glu1038_Glu1042del 1 0.2447 rs774012136 Benign Yes
c.3074T>G p.Val1025Gly 1 0.0169 rs773842474 Likely benign Yes No
c.3062T>G p.Val1021Gly 1 0.8368* rs144299434 Likely benign Yes No
c.2964_2965del p.Glu989GlyfsTer89 2 NA Pathogenic Yes Yes 1
c.2919_2939dup p.Gly977_Glu983dup 13 1.0322* rs772859148 VUS No Yes †
c.2937_2938del p.Glu980GlyfsTer98 1 NA Pathogenic Yes Yes 2
c.2863T>G p.Trp955Gly 47 19.7002 rs765224300 Benign Yes No †
c.2820_2840dup p.Asp943_Glu949dup 5 3.3006 rs764268405 Benign No Yes
c.2829T>G p.Asp943Glu 1 1.4892 rs201655057 Likely benign Yes
c.2829T>A p.Asp943Glu 1 0.133 rs201655057 Likely benign Yes
c.2820A>G p.= 1 NA VUS No No
c.2790_2791del p.Glu931GlyfsTer147 2 NA Pathogenic Yes Yes 3
c.2778_2786del p.Glu927_Glu929del 1 NA VUS Yes
c.2758A>G p.Lys920Glu 4 0.0548 rs1241379586 Likely benign Yes No †
c.2705G>A p.Gly902Glu 1 NA Likely benign Yes










1 NA VUS No Yes
c.2655_2656del p.Glu886GlyfsTer192 1 NA Pathogenic Yes Yes 4
c.2639A>G p.Glu880Gly 1 NA Likely benign Yes Yes
c.2633_2634delinsAA p.Gly878Glu 1 NA Likely benign Yes Yes
c.2618_2632dup p.Glu873_Glu877dup 5 NA VUS No Yes †
c.2606_2632dup p.Glu869_Glu877dup 6 NA rs769216492 VUS No Yes †
c.2569A>G p.Lys857Glu 6 0.981 rs1250133030 Likely benign Yes No †
c.2541_2561del p.Glu850_Gly856del 12 2.0962 rs886038384 Likely benign No Yes †
c.2514G>A p.= 1 NA VUS Yes
Genes 2020, 11, 800 7 of 17
Table 1. Cont.
cNomen (NM_001034853.2) pNomen # of Samples gnomAD (%) rsID Pathogenicity Std Pipeline Sanger First Report
c.2499T>G p.= 1 0.0406 rs752979508 Likely benign Yes No
c.2470_2471del p.Gly824ArgfsTer10 2 NA Pathogenic Yes Yes This study
c.2457_2460del p.Glu820ArgfsTer268 1 NA Pathogenic Yes Yes This study
c.2341G>A p.Ala781Thr 2 12.1386 rs5917557 Benign Yes
c.2236_2237del p.Glu746ArgfsTer23 1 NA Pathogenic Yes Yes 5
c.2223G>A p.= 15 10.3568 rs147619484 Benign Yes Yes †
c.2057T>A p.Met686Lys 1 0.449 rs151247357 Likely benign Yes
c.1961G>A p.Arg654Lys 1 NA Likely benign Yes No
c.1933G>A p.Gly645Arg 1 NA Likely benign Yes No
c.1754-103C>T 15 10.1753 rs41303691 Benign Yes
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In contrast, Table 2 displays all variants passing all quality filters identified by the standard
pipeline. It highlights how often each distinct variant has been called in the cohort by either secondary
analysis pipeline. There is a remarkable discordance between the pipelines’ outputs. Each variant on
Table 2 was assigned a call quality (either high or low) based on accordance with the novel pipeline’s
results. High-quality calls were assigned to variants with complete concordance with the novel
pipeline’s results.
Assuming all low-quality calls are false positive, the standard pipeline resulted in 516 false positive
calls, whilst the novel pipeline produced 65 false positives. Unfortunately, it was not possible to test all
discrepancies by Sanger sequencing. Instead, at least one carrier sample per discrepant variant was
selected for Sanger sequencing to confirm the presence or absence of the respective variant.
Variants c.3074T>G, c.3062T>G, c.2863T>G, c.2758A>G, and c.2499T>G were called in most
samples by the standard pipeline (in 80, 74, 81, 75, and 65 samples, respectively), but they were
found only once by the novel pipeline (except for c.2863T>G, which was called in 47 samples and
c.2758A>G in 4 samples). Moreover, the standard pipeline resulted in heterozygous calls exclusively,
which we considered a low-quality variant marker. Sanger sequencing revealed these variants to be
false positives in the tested subset (8 samples).
Variants c.2829T>G and c.2829T>A show a similar pattern; they were called in 50 and 30 samples,
respectively, from the standard pipeline and only once by the novel pipeline. Both variants were
confirmed to be false positive in 4 and 3 samples, respectively. Interestingly, these variants overlap
with the c.2820_2840dup variant that has been identified by the novel pipeline in a subset of the
corresponding samples. Even more striking is the overlap of samples carrying the c.2639A>G,
c.2634G>A, c.2633G>A, and c.2589A>G variants in the standard pipeline’s outputs with those carrying
the c.2606_2632dup variant in the novel pipeline’s output. All of the former variants were confirmed as
false positives in a subset of the carriers, and the latter was confirmed as being present. These findings
highlight that some of the standard pipeline’s false positive cluster around the region, where the novel
pipeline identified indels.
All remaining low-quality call variants were not found in the novel pipeline’s output (except for
c.2569A>G, which was called in 6 samples), and all those that could be verified by Sanger sequencing
were confirmed to be false positives.
In contrast, all high-quality call variants tested could be confirmed, except for 2 variants from
sample Afr-31, which is one out of five samples with an average coverage lower than 100×. It is
noteworthy that most variants identified in these low-coverage samples are confirmed false positives
(except for c.125delA, c.2606_2632dup, which could not be tested in these samples), suggesting that
very deep coverage might be needed to result in high-quality variant calls with the novel pipeline.
Variants c.3407G>A, c.3396C>T, c.3264G>A, c.3219C>T, and c.2667_2669del were identified in one
additional sample by standard analysis compared to the novel pipeline outputs; all missing samples
were females called as heterozygous by the standard pipeline. These results seem to suggest that the
novel pipeline might produce false negatives in female carriers. However, other heterozygous variants
in female carriers were detected by the novel pipeline (c.2341G>A, c.2223G>A, c.1754-103C>T).
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Table 2. Standard secondary analysis pipeline variants passing quality filters. Column four highlights how often the variant had been called as heterozygous and how
many of these were from male samples. Column six shows whether the variant had been identified by the novel pipeline and in how many samples. Sanger sequences
were used to confirm the presence or absence of the variant. Variants highlighted in grey, and in italics are confirmed false positives. Bold orange variants were
considered pathogenic. † denotes variants for which only a subset of samples was verified by Sanger.
cNomen
(NM_001034853.2)




c.3407G>A p.Gly1136Asp 3 2 (0) 1 Yes (2) High
c.3396C>T p.= 5 2 (0) 3 Yes (4) High
c.3356G>A p.Arg1119Lys 1 1 (1) 0 No Low
c.3264G>A p.= 15 4 (0) 11 Yes (14) High
c.3219C>T p.= 15 4 (0) 11 Yes (14) High Yes †
c.3178_3179del p.Glu1060ArgfsTer18 1 0 (0) 1 Yes (1) High Yes
c.3108_3122del p.Glu1038_Glu1042del 1 0 (0) 1 Yes (1) High
c.3074T>G p.Val1025Gly 80 80 (64) 0 Yes (1) Low No †
c.3062T>G p.Val1021Gly 74 74 (58) 0 Yes (1) Low No †
c.2964_2965del p.Glu989GlyfsTer89 2 2 (2) 0 Yes (2) High Yes
c.2937_2938del p.Glu980GlyfsTer98 1 1 (1) 0 Yes (1) High Yes
c.2895G>A p.= 8 8 (7) 0 No Low No †
c.2876A>G p.Glu959Gly 1 1 (1) 0 No Low No
c.2863T>G p.Trp955Gly 81 81 (65) 0 Yes (47) Low No †
c.2847A>G p.= 1 1 (1) 0 No Low No
c.2829T>G p.Asp943Glu 50 50 (44) 0 Yes (1) Low No †
c.2829T>A p.Asp943Glu 30 40 (23) 0 Yes (1) Low No †
c.2790_2791del p.Glu931GlyfsTer147 2 2 (2) 0 Yes (2) High Yes
c.2778_2786del p.Glu927_Glu929del 1 0 (0) 1 Yes (1) High
c.2784A>G p.= 1 1 (1) 0 No Low No
c.2758A>G p.Lys920Glu 75 75 (59) 0 Yes (4) Low No †
c.2705G>A p.Gly902Glu 1 1 (1) 0 Yes (1) High
c.2667_2669del p.Glu890del 2 1 (0) 1 Yes (1) High
c.2655_2656del p.Glu886GlyfsTer192 1 1 (1) 0 Yes (1) High Yes
c.2639A>G p.Glu880Gly 6 6 (6) 0 Yes (1) Low No †
c.2634G>A p.= 6 6 (6) 0 Yes (1) Low No †
c.2633G>A p.Gly878Glu 6 6 (6) 0 Yes (1) Low No †
c.2589A>G p.= 7 7 (6) 0 No Low No †
c.2569A>G p.Lys857Glu 11 11 (9) 0 Yes (6) Low No †
c.2531A>G p.Glu844Gly 1 1 (0) 0 No Low








c.2517A>G p.= 11 11 (10) 0 No Low No †
c.2514G>A p.= 1 1 (1) 0 Yes (1) High
c.2499T>G p.= 65 65 (54) 0 Yes (1) Low No †
c.2470_2471del p.Gly824ArgfsTer10 2 0 (0) 2 Yes (2) High Yes
c.2457_2460del p.Glu820ArgfsTer268 1 0 (0) 1 Yes (1) High Yes
c.2341G>A p.Ala781Thr 2 1 (0) 1 Yes (2) High
c.2236_2237del p.Glu746ArgfsTer23 1 0 (0) 1 Yes (1) High Yes
c.2223G>A p.= 15 3 (0) 12 Yes (15) High Yes †
c.2057T>A p.Met686Lys 1 0 (0) 1 Yes (1) High
c.1961G>A p.Arg654Lys 1 1 (1) 0 Yes (1) High No
c.1933G>A p.Gly645Arg 1 1 (1) 0 Yes (1) High No
c.1885G>A p.Asp629Asn 1 1 (1) 0 No Low No
c.1754-103C>T 15 10.1753 rs41303691 Benign Yes
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Figure 1 visually summarises the findings contained in Tables 1 and 2 by illustrating the numbers
of overall and unique true and false positives identified by each pipeline. It is important to point
out once more that each unique variant call, which is present in multiple samples, has been Sanger
verified in a subset of those. However, since all of them are concordant, all such variant calls have been
considered as “confirmed” false or true positives in Figure 1.have been considered as “confirmed” false or
category that has been verified by Sanger sequencing (Confirmed†) and those that could not be 
1 and 2, the Confirmed† categories include all variants that 
Figure 1. Nested pie plots highlighting the proportion of true versus false positive variant calls
produced by the standard and novel pipelines. Blue shaded portions represent true positives; red
portions illustrate false positive calls. The top charts summarise all variant calls (n = 606 and n = 244
variant calls in standard and novel pipelines, respectively), and the bottom charts represent all unique
variants (n = 43 and n = 41 variants, respectively). The inner rings show the proportion of each category
that has been verified by Sanger sequencing (Confirmed†) and those that could not be confirmed
(Assumed). As listed in Tables 1 and 2, the Confirmed† categories include all variants that have been
confirmed in at least a subset of samples.
3.3. Segregation Analysis
Eight pathogenic variants were confirmed in 11 families by Sanger sequencing (Figure 2). The lack
of familial DNA samples was a limitation in this study, as is often the case in human genetic studies.
Additional challenges were (a) amplification failure for some samples, possibly due to variants in the
primer-binding regions, and (b) the presence of multiple indels in female carriers which confounded
analysis and interpretation.
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successful amplification. Most publications only report “positive results” and do not comment on 
Figure 2. Pedigrees of 11 families with verified pathogenic open reading frame 15 (ORF15) mutations.
Squares represent males, and circles, females. Shaded symbols indicate individuals affected with
inherited retinal disorders (IRDs), and hatched symbols indicate individuals with undiagnosed visual
problems. Identifier codes show individuals from whom biological material was available, and those
selected for next-generation sequencing (NGS) are noted with an asterisk. Segregation of the mutation
in the families is indicated as: M (hemizygous mutation); M/+ (heterozygous mutation).
4. Discussion
In this study, we identified pathogenic RPGR ORF15 variants in 13% (n = 11/82 probands) of
an African IRD cohort comprising isolated affected males and families lacking male-to-male disease
transmission. A total of 32 unique variants were identified (18 validated by Sanger sequencing),
including novel pathogenic frameshift mutations.
The prevalence of small indels in RPGR exon ORF15 (57 in 82 samples sequenced in this cohort)
indicate that the replication of this region in vivo is demanding and error-prone. This might explain,
at least partly, the challenge of amplification in vitro. In fact, PCR amplification failed several times,
for both NGS (n = 15/97 samples; 15% of the cohort) and Sanger protocols (n = 5/33 samples; 15% of the
cohort). On the other hand, it is possible that variants in the primer-binding regions prevent successful
amplification. Most publications only report “positive results” and do not comment on amplification
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failure. ORF15 is a known troublesome region, and it would be valuable to know what proportion of
ORF15 amplifications fail, in particular for older DNA samples, in other laboratories.
Heterozygous variant calls resulting from the standard secondary analysis pipeline (BWA-MEM
and GATK) in male samples highlighted problems that occurred during alignment and/or variant
calling across this low-complexity region. Furthermore, we identified 516 potential false positives
produced by the standard pipeline, which passed all quality filters (85% of all variant calls). We were
able to circumvent the problem by developing an alternative secondary analysis pipeline based on
de novo assembly. This analysis allowed for the identification of otherwise missed variants, in particular
indels larger than 15 bp. By comparing the results of both data analysis pipelines, we showed that
the novel method is more sensitive (in particular for indels) and less prone to false positive calls,
as illustrated in Figure 1. The novel pipeline produced a maximum of 67 potential false positive calls,
47 of which are accounted for by a single variant (c.2863T>G). The results seem to suggest superiority
of the newly developed analysis method, in terms of sensitivity and specificity.
However, the continued identification of false positives in the novel pipeline’s output warrants
caution in results interpretation. All of these (except for c.2820A>G) were present in the standard
pipeline’s output, too. Furthermore, the unavailability of verified true heterozygous variants in female
probands (16 included in this study) made it impossible to verify how the pipeline will perform in the
presence of two alleles. Sanger sequencing ORF15 in females can be very complicated due to the high
frequency of small indels (often heterozygous in females), which shift the frame of the Sanger traces
and can hinder its analysis. Moreover, this problem affects all other current methodologies in the case
of ORF15. Based on this, we recommend the parallel use of both pipelines for the analysis of RPGR’s
ORF15 by NGS and to perform the analysis on affected males where possible.
Our analysis of the African cohort identified a large number (n = 15/32 as listed on Table 1;
47%) of variants not represented in gnomAD and lacking an rs ID, which we have to presume
are novel or rare. The count is inflated by variants from samples Afr-61 and Afr-31; as discussed
above, Afr-61 is reported to carry three novel variants, but the more conservative variant calls
described above would reduce it to one novel and one very rare variant. Afr-31 contributes
four additional novel variants, two of which were not present on Sanger sequences, whilst the
remaining two could not be verified. Therefore, a more conservative count lists 10 novel variants
out of 28 unique variants (35%). However, it is possible that these variants have been missed by
gnomAD, and others, due to complications with the capture or alignment of this genomic region,
and this limitation should be noted. Nevertheless, this work once again underscores the genetic
diversity of the understudied African populations and highlights their value in molecular studies by
(1) contributing towards a more comprehensive global catalogue of disease-causing mutations and
(2) providing additional information for pathogenicity interpretation. For example, the ‘novel’ variants
of uncertain clinical significance c.2606_2632dupAAGAAGGGGAGGAAGGAGAAGGGGAGG and
c.2618_2632dupAAGGAGAAGGGGAGG are relatively common in the indigenous African study cohort
(9% and 6% of the cohort, respectively), providing supporting evidence that they are likely benign.
Two novel pathogenic frameshift mutations, namely c.2457_2460delAGAG and c.2470_2471delGG,
were identified. The latter mutation was recurrent in two families, Afr-63 and Afr-65, both of unknown
ethnolinguistic origin. Similarly, the c.2790_2791delGG pathogenic variant was identified in two
additional families in this cohort, bringing the total to four indigenous African families of different
ethnolinguistic groups; two previously identified large Xhosa families (Figure S1A,B), as well as
Afr-16 (ethnicity was not reported) and Afr-71 (self-identified as Tswana) in this cohort (Figure 2).
The Sotho-Tswana and Xhosa groups show significant genetic differences, despite recent geographic and
linguistic divergence [30]. Although we cannot exclude gene flow after divergence, c.2790_2791delGG
is possibly an ancient mutation from a common ancestor and could be relatively prevalent in
SA. In addition, a third recurrent pathogenic mutation was identified, namely c.2964_2965delGG
(in self-reported Zulu/Swazi individual Afr-60, and two Xhosa families i.e., Afr-75, and the previously
identified family in Figure S1C). These three recurrent mutations (c.2470_2471delGG, c.2790_2791delGG
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and c.2964_2965delGG) provide a possible target for an initial population-relevant, cost-effective
diagnostic screen, as combined they account for 9/14 (64%) of ORF15-associated indigenous African
families identified to date.
Phenotypically, all probands identified with pathogenic mutations manifested with early-onset
RP. The exception was Afr-38, which was diagnosed with rod-cone macular degeneration and a
self-reported onset age of 36. Whilst cone involvement is not unusual at an advanced stage of RP, this
onset-age outlier is likely due to a combination of factors such as language barriers and limited access
to ophthalmological services in SA.
Approximately half of the resolved African families showed manifesting female carriers (Figure 2).
In SA’s resource-limited environment, special consideration should therefore be given to pre-screening
ORF15 in apparently dominant pedigrees lacking male-to-male transmission and exhibiting early
disease onset, prior to costly WES, which would have almost certainly missed the causal variants.
Expanding on this approach, the 71 probands that have been excluded from harbouring causal ORF15
mutations are now eligible for NGS screening (either via WES or targeted capture of remaining
candidate genes), in the hopes of finding the genetic causes of blindness.
Finally, the genetic diagnosis achieved by our new sequence data analysis pipeline will impact
the care and counselling for these 11 patients and their extended families. Identification of the
underlying mutations allows for diagnostic closure and enables calculation of the risk of developing
the disease, thereby facilitating decision making and life choices. Importantly, a molecular diagnosis
may also determine eligibility for a potentially available gene-based and personalised therapy
(https://clinicaltrials.gov/ct2/show/NCT03116113) and/or other treatments and interventions in order to
preserve vision.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4425/11/7/800/s1,
Figure S1: Pedigrees of three families identified with RPGR ORF15 mutations by commercial sequencing, after WES
failed to resolve the causal mutations, Zipped Folder S2 Folder containing the JupyterLab notebook and the
required folder structures and accessory files, HTML S3: alternative pipeline overview in HTML format.
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